ARTICLE | Clinical News

Adverse event consortium begins second phase

October 1, 2010 12:13 AM UTC

The International Serious Adverse Events Consortium (SAEC) began the second phase of ongoing research to identify genetic markers that could predict which patients are at risk of rare drug-related adverse events. Goals for the second phase include completing two genomewide genotyping studies focused on co-amoxiclav liver injury and clozapine agranulocytosis to investigate the role of low frequency variants in serious adverse event risk; and establishing an acute hypersensitivity reaction research network. Last year, the consortium published data from the study's first phase that showed patients carrying the HLA-B 5701 allele were more likely than non-carriers to develop flucloxacillin-induced liver injury. ...